In summary, our findings suggest that exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in ESCC cells, and exosomal PART1 levels in human serum may be considered a potential diagnostic biomarker for ESCC patients, enhancing the clinical benefits of gefitinib therapy. This evidence concerns the gene PART1 and esophageal squamous cell carcinoma.